Pittsburgh, Pennsylvania, United States - Sunday, April 10th 2016 [ME NewsWire]
Cellogique Corporation is pleased to announce the launch of CeraVe® skin care products in the Middle East under a distribution agreement with Valeant DWC. Cellogique and Valeant DWC intend to introduce CeraVe® products, for the first time, in pharmacies and drugstores across the region.
Mr. Mazen F. Youssef, President and CEO of Cellogique Corporation, states, “We are very excited to have the opportunity to bring CeraVe® to the Middle East. This highly anticipated line will complement our portfolio of therapeutic skin care brands.” As one of the fastest growing names in skin care and of the core dermatology brands of Valeant DWC, Cellogique expects CeraVe® to exceed multimillion dollar sales in the Middle East region.
“We are pleased to continue and increase our partnership with Cellogique Corporation,” stated Mr. Muhittin Bilgutay, Valeant DWC Vice President of the Middle East, Turkey, and Africa. “We trust this collaboration will help to build CeraVe® in the Middle East while the brand has already proven its success in the United States and around the world.”
Mr. Bilgutay continues, “Launching the CeraVe® range in the Middle East shows the consistency of our global strategy. Our company focuses on faster growing geographies and this launch is another milestone in our journey to expand Valeant assets to our growth platform in the Middle East”.
CeraVe® is a range of skin care products with essential ceramides and other skin-nourishing and skin-moisturizing ingredients (humectants and emollients) combined with a unique, patented Multivesicular Emulsion (MVE®) delivery technology that, together, work to rebuild and repair the skin barrier. CeraVe® formulations incorporate ceramides, cholesterol, and fatty acids, all of which are essential for skin barrier repair and are used as adjunct therapy in the management of various skin conditions.
Developed with dermatologists, CeraVe® has a full line of products recommended for face and body to address not only dry or oily skin, but also for use as part of a recommended skin care regimen suitable for those with skin conditions such as eczema, psoriasis, acne, rosacea, and atopic dermatitis. CeraVe® products are non- irritating, non-comedogenic, and fragrance-free.
Valeant Pharmaceuticals International, Inc.
Valeant DWC is the Middle East entity of Valeant Pharmaceuticals International, a multinational specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed in more than 100 countries.
Cellogique Corporation
Cellogique Corporation has been pioneering the world of cosmetic surgery, medical aesthetics, and skin health for several years throughout the Middle East region. With more than 5 subsidiary offices around the world, Cellogique continues to grow and expand each year, introducing new concepts and innovative ideas in the cosmetic services industry. Cellogique’s unique business model focuses on specializing in the distribution of pharmaceutical strength skin care products as well as developing cosmetic surgery centers and retail store venues.
Cellogique Corporation’s innovative approach on medical aesthetics led to the concept and development of Obagi MediSpas. Cellogique Corporation and Obagi MediSpas are committed to providing the best in cosmetic treatments, procedures, and products that are both effective and safe.
Contacts
Cellogique Corporation
Assaad Atallah, +9714-299-8550
Fax: +9714-299-8551
info@verticalprogress.ae
assaad.atallah@cellogique.ae
Permalink: http://me-newswire.net/news/17563/en
Cellogique Corporation is pleased to announce the launch of CeraVe® skin care products in the Middle East under a distribution agreement with Valeant DWC. Cellogique and Valeant DWC intend to introduce CeraVe® products, for the first time, in pharmacies and drugstores across the region.
Mr. Mazen F. Youssef, President and CEO of Cellogique Corporation, states, “We are very excited to have the opportunity to bring CeraVe® to the Middle East. This highly anticipated line will complement our portfolio of therapeutic skin care brands.” As one of the fastest growing names in skin care and of the core dermatology brands of Valeant DWC, Cellogique expects CeraVe® to exceed multimillion dollar sales in the Middle East region.
“We are pleased to continue and increase our partnership with Cellogique Corporation,” stated Mr. Muhittin Bilgutay, Valeant DWC Vice President of the Middle East, Turkey, and Africa. “We trust this collaboration will help to build CeraVe® in the Middle East while the brand has already proven its success in the United States and around the world.”
Mr. Bilgutay continues, “Launching the CeraVe® range in the Middle East shows the consistency of our global strategy. Our company focuses on faster growing geographies and this launch is another milestone in our journey to expand Valeant assets to our growth platform in the Middle East”.
CeraVe® is a range of skin care products with essential ceramides and other skin-nourishing and skin-moisturizing ingredients (humectants and emollients) combined with a unique, patented Multivesicular Emulsion (MVE®) delivery technology that, together, work to rebuild and repair the skin barrier. CeraVe® formulations incorporate ceramides, cholesterol, and fatty acids, all of which are essential for skin barrier repair and are used as adjunct therapy in the management of various skin conditions.
Developed with dermatologists, CeraVe® has a full line of products recommended for face and body to address not only dry or oily skin, but also for use as part of a recommended skin care regimen suitable for those with skin conditions such as eczema, psoriasis, acne, rosacea, and atopic dermatitis. CeraVe® products are non- irritating, non-comedogenic, and fragrance-free.
Valeant Pharmaceuticals International, Inc.
Valeant DWC is the Middle East entity of Valeant Pharmaceuticals International, a multinational specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices) which are marketed in more than 100 countries.
Cellogique Corporation
Cellogique Corporation has been pioneering the world of cosmetic surgery, medical aesthetics, and skin health for several years throughout the Middle East region. With more than 5 subsidiary offices around the world, Cellogique continues to grow and expand each year, introducing new concepts and innovative ideas in the cosmetic services industry. Cellogique’s unique business model focuses on specializing in the distribution of pharmaceutical strength skin care products as well as developing cosmetic surgery centers and retail store venues.
Cellogique Corporation’s innovative approach on medical aesthetics led to the concept and development of Obagi MediSpas. Cellogique Corporation and Obagi MediSpas are committed to providing the best in cosmetic treatments, procedures, and products that are both effective and safe.
Contacts
Cellogique Corporation
Assaad Atallah, +9714-299-8550
Fax: +9714-299-8551
info@verticalprogress.ae
assaad.atallah@cellogique.ae
Permalink: http://me-newswire.net/news/17563/en
No comments:
Post a Comment